Gaxiola E, Ramírez-Sánchez U

Idioma: Español
Referencias bibliográficas: 25
Paginas: 269-274
Archivo PDF: 110.76 Kb.

RESUMEN

Durante la última década, la mortalidad del choque cardiogénico ha disminuido significativamente debido a la implementación de estrategias de reperfusión coronaria asociadas al uso de balón intraaórtico de contrapulsación. Sin embargo, a pesar de estas medidas la mortalidad es aún muy elevada. Actualmente y en los siguientes años, las medidas están encaminadas a acortar los tiempos para lograr la reperfusión coronaria y diferentes estrategias para preservar y prolongar la viabilidad celular miocárdica.

REFERENCIAS (EN ESTE ARTÍCULO)

1. GOLDBERG, RJ, GORE, JM, THOMPSON, CA, GURWITZ JH: Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction. Am Heart J 2001; 141: 65.

2. HOLMES DR JR, BATES ER, KLEINMAN NS, ET AL: Contemporary reperfussion therapy for cardiogenic shock: The GUSTO-I trial experience. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26: 668.

3. HOLMES DR JR, BERGER PB, HOCHMAN, JS ET AL: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100: 2067.

4. GOLDBERG RJ, GORE JM, ALPERT JS, ET AL: Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community wide perspective, 1975-1988. N Engl J Med 1991; 325: 1117.

5. HASDAI D, HARRINGTON RA, HOCHMAN JS, ET AL: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36: 685.

6. HANDS ME, RUTHERFORD JD, MULLER JE, ET AL: The in-hospital development of cardiogenic shock after myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors. J Am Coll Cardiol 1989; 14: 40.

7. HOCHMAN JS, SLEEPER LA, WHITE HD, ET AL: Oneyear survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-192.

8. GIRI S, MITCHEL J, AZAR RR, ET AL: Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002; 89: 126.

9. CHAN AW, CHEW DP, BHATT DL, ET AL: Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002; 89: 132.

10. ANTMAN EM, ANBE DT, ARMSTRONG PW, ET AL: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588.

11. WEBB JG, SANBORN TA, SLEEPER SCD, CARERE RG, BULLER CE, SLATER JN, ET AL: Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J 2001; 141: 964-70.

12. HOCHMAN JS: Cardiogenic shock complicating acute myocardial infarction. Expanding the paradigm. Circulation 2003; 107: 2998-3002.

13. MARTÍNEZ-RÍOS MA, ROSAS M, GONZÁLEZ H, ET AL: Relevance of the combined TIMI flow/perfusion index to effective assessment of reperfussion regimens with or without tirofiban in ST-elevation myocardial infarction. Insights from SASTRE-STEMI study, a randomized clinical trial. Am J Cardiol 2004; 93: 280-287.

14. MONTALESCOT G, BORENTAIN M PAYOT L, ET AL : Early vs late administration of glycoprotein IIb/ IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. A meta-analysis. JAMA 2004; 292: 362-66.

15. GOROG DA, FOALE RA, MALIK I: Distal myocardial protection during percutaneous coronary intervention. When and where? J Am Coll Cardiol 2005; 46: 1434-45.

16. BERANEK JT: C-reactive protein and complement in myocardial infarction and postinfarction heart failure. Eur Heart J 1997; 18: 1834-1836.

17. MATHEY D, SCHOFER J, SCHAFER HJ, HAMDOCH T, JOACHIM HC, RITGEN A. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfussion. Eur Heart J 1994; 15: 418-423

18. MAHAFFEY KW, GRANGER CB, NICOLAU JC, RUZYLLO W, WEAVER WD, THEROUX P, ET AL: Effect of Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolisis in acute myocardial infarction. The COMPLY Trial. Circulation 2003; 108: 1176-83.

19. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMMA Trial. Circulation 2003; 108: 1184-90.

20. COTTER G, KALUSKI E, MILO O, BLATT A, SALAH A, HENDLER A, ET AL: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogénico shock. A prospective randomized study. Eur Heart J 2003; 24: 1287-95.

21. The Hypothermia after Cardiac Arrest Study Group. Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest. N Engl J Med 2002; 346: 549-556.

22. ROSS AM, GIBBONS RJ, STONE GW, KLONER RA, ALEXANDER RW for the AMISTAD-II Investigators A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfussion in the Treatment of Acute Myocardial Infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.

23. The CREATE-ECLA Trial Group Investigators*. Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial. JAMA 2005; 293: 437-446.

24. KLONER RA, REZKALLA SH: Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 2004; 44: 276-86.

25. DIMMELER S, ZEIHER AM: Wanted! The best cell for cardiac regeneration. J Am Coll Cardiol 2004; 44: 464-466.